Adagio Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc. (historical ticker: ADGI) was a US-listed biotechnology company that traded on the NASDAQ market in the United States. For investors screening SEC Form 4 insider activity, an important point is that Adagio later changed its corporate name to Invivyd, Inc. in September 2022; accordingly, ADGI is a historical ticker and no longer the company’s active trading symbol, although it can still appear in legacy SEC filings. The company was headquartered in Waltham, Massachusetts, with a research footprint in the greater Boston area, and it was built around an antibody-discovery platform focused on viral threats. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1832038/000119312522243285/d388436d8k.htm?utm_source=openai)) Adagio was founded in the late 2010s and launched with a Series A financing to advance broadly neutralizing antibodies for coronavirus treatment and prophylaxis. It later raised substantial capital, including a $336 million Series C round in 2021, which was intended to accelerate development of its lead asset ADG20 and broaden the pipeline. Strategically, the company positioned itself as a clinical-stage biopharmaceutical developer in infectious disease, with a special emphasis on pathogens with pandemic potential rather than on a diversified multi-therapy portfolio. That narrow focus gave Adagio a clearly defined scientific story, but it also exposed the business to high clinical and regulatory execution risk typical of development-stage biotech companies. ([investors.adagiotx.com](https://investors.adagiotx.com/news-releases/news-release-details/adagio-therapeutics-announces-336-million-series-c-financing/?utm_source=openai)) In operating terms, Adagio concentrated on discovering, developing, and commercializing antibody-based solutions for respiratory viral diseases, especially COVID-19. Its lead program, ADG20, was designed as a broadly neutralizing antibody intended to retain activity across variants and potentially against future coronavirus outbreaks. This placed the company in a competitive biotech niche alongside larger pharmaceutical groups, specialist antibody developers, and pandemic-preparedness efforts supported by public and private capital. The investment case was therefore based on differentiated science, speed of clinical development, and the ability to convert that science into regulatory progress and commercial agreements. ([investors.adagiotx.com](https://investors.adagiotx.com/news-releases/news-release-details/adagio-therapeutics-announces-336-million-series-c-financing/?utm_source=openai)) Geographically, the company’s operations were primarily US-based, with headquarters and laboratory activity centered in Massachusetts. Its listing on NASDAQ in the United States made it part of the small-cap biotechnology universe, where valuation is highly sensitive to trial data, financing needs, and regulatory milestones. The key recent corporate event was the name change to Invivyd, effective September 13, 2022, together with the ticker change from ADGI to IVVD. For investors, that means historical ADGI references should be interpreted as legacy disclosures from the company’s earlier corporate identity, not as a separate still-listed entity. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1832038/000119312522243285/d388436d8k.htm?utm_source=openai))